In the latest quarter, 9 analysts provided ratings for Legend Biotech LEGN, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 5 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 4 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $86.33, a high estimate of $94.00, and a low estimate of $81.00. Observing a 2.17% increase, the current average has risen from the previous average price target of $84.50.
Investigating Analyst Ratings: An Elaborate Study
The standing of Legend Biotech among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| Ashwani Verma | UBS | Raises | Buy | $81.00 | $76.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| Sean McCutcheon | Raymond James | Announces | Outperform | $86.00 | - |
| Leonid Timashev | RBC Capital | Maintains | Outperform | $85.00 | - |
| Leonid Timashev | RBC Capital | Maintains | Outperform | $85.00 | - |
| Leonid Timashev | RBC Capital | Maintains | Outperform | $85.00 | - |
| Gena Wang | Barclays | Raises | Overweight | $94.00 | $93.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Legend Biotech. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Legend Biotech compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Legend Biotech's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Legend Biotech's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Legend Biotech analyst ratings.
All You Need to Know About Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Breaking Down Legend Biotech's Financial Performance
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Legend Biotech's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 187.57% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Legend Biotech's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -182.24%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Legend Biotech's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -11.18%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.85%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Legend Biotech's debt-to-equity ratio is below the industry average. With a ratio of 0.26, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Significance of Analyst Ratings Explained
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
